ResMed vs Solventum
RMD and SOLV side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RMD and SOLV compare
ResMed is the larger company, worth 2.2 times as much as Solventum ($33.7B against $15.2B).
On earnings, ResMed is cheaper: it trades at 21.8× trailing earnings, against 100× for Solventum.
ResMed grew revenue faster over the last twelve months (9.0% versus −2.8% for Solventum).
ResMed keeps more of each dollar of sales as profit, with a net margin of 27.8% compared with 1.9% at Solventum.
ResMed pays a dividend yielding 0.78%; Solventum does not pay one.
ResMed scores higher on the StockData Score (21 against 6 for Solventum), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RMD | SOLV |
|---|---|---|
| Size and price | ||
| Market cap | $33.7B | $15.2B |
| Share price | $239.53 | $89.08 |
| Change, 1 year | −5.3% | 20.7% |
| Change, 5 years | −8.0% | – |
| Beta (5Y) | 0.92 | 0.52 |
| Employees | 11K | 10K |
| StockData Score | ||
| Total score | 21 (better) | 6 |
| Valuation score | 4 (better) | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 6 (better) | 2 |
| Health score | 4 (better) | 1 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 21.8× (better) | 100× |
| P/S | 5.9× | 1.9× (better) |
| P/B | 5.7× | 3.2× (better) |
| EV/EBITDA | 15.7× (better) | 20.3× |
| P/FCF | 20.9× | – |
| PEG | 1.11 (better) | 22.21 |
| FCF yield | 4.8% (better) | 0.00% |
| Fair value | $271.23 | $45.61 |
| Margin of safety | 11.7% (better) | −95.3% |
| Growth | ||
| Revenue growth (TTM) | 9.0% (better) | −2.8% |
| Revenue growth, 5Y average | 12.1% | – |
| Net income growth (TTM) | 10.8% (better) | −89.8% |
| EPS growth (TTM) | 12.4% (better) | −89.8% |
| EPS growth, 5Y average | 26.3% | – |
| Profitability | ||
| Gross margin | 61.1% (better) | 54.8% |
| Operating margin | 33.0% (better) | 5.6% |
| Net margin | 27.8% (better) | 1.9% |
| FCF margin | 28.1% (better) | 0.00% |
| Return on equity | 26.4% (better) | 3.2% |
| Return on invested capital | 29.7% (better) | 4.7% |
| Financial health | ||
| Debt / equity | 0.03 (better) | 1.05 |
| Net debt / EBITDA | −0.41 | 4.74 (better) |
| Current ratio | 2.65 (better) | 1.03 |
| Altman Z-score | 12.00 (better) | 1.85 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.78% | – |
| Payout ratio | 22.4% | – |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 9.0% | – |
| Buyback yield | 4.2% | – |
| Shareholder yield | 5.0% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 71.1% | 75.0% |
| Held by insiders | 1.3% | 30.3% |
| Insider net buying, 12 months | −$19.6M | $100K (better) |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | – | 4.3% |
Go deeper
- RMD stock overview
- RMD income statement
- RMD valuation and score
- SOLV stock overview
- SOLV income statement
- SOLV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.